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“Beginnings are usually scary and endings are usually sad, but it’s everything in between that 
makes it all worth living”  
- Bob Marley 
  
  
  
ABSTRACT 
The inflammatory bowel diseases (IBD) Crohn’s disease (CD) and ulcerative colitis (UC) 
are conditions characterized by chronic and relapsing inflammation of the gastrointestinal 
tract. IBD affects around 2.5 million people of European ancestry and the incidence is 
increasing worldwide (currently, 1% of the population suffers from IBD in Sweden). IBD 
patients require life-long medication, hospitalizations, recurring sick-leaves, surgical 
intervention and may acquire serious complications, such as colorectal cancer. There is as 
yet no definitive cure, and new treatment modalities are effective, but far from being 
optimal. A much greater understanding of IBD pathophysiology is therefore needed, in order 
to delineate improved therapeutic strategies, and to predict disease course and response to 
treatment. 
Although the etiology of IBDs is unknown, current consensus is that they occur in genetically 
predisposed individuals, primarily due to a dysregulated immune response to gut microbiota. 
IBD genetic research has highlighted the importance of innate immune interactions with the 
gut microbiota, the regulation of immune functions, the maintenance of gut epithelial barrier, 
and autophagy in order to maintain gut homeostasis. However, these discoveries have not yet 
led to the identification of novel pathogenetic pathways that may be amenable to exploitation 
for renewed therapeutic intervention. Eventually, this may come from the study of risk genes 
of unknown function. 
The overall aim of this thesis is the functional characterization of novel gastrointestinal 
disease genes, and in particular the Laccase (multicopper oxidoreductase) domain-containing 
1 (LACC1) gene, in order to elucidate the mechanism(s) by which its genetic variation(s) 
contributes to IBD, and ultimately provide novel opportunities for therapeutic exploitation.  
In paper I, we tested a series of LACC1 common variants for association with disease in two 
Swedish cohorts of IBD and non-systemic juvenile idiopathic arthritis (nsJIA). Significant 
findings were detected for multiple LACC1 markers in the studied cohorts, thereby expanding 
previous results for CD to both UC and nsJIA. 
In paper II, we identified FAMIN (the LACC1 encoded protein) as a core metabolic 
regulator of macrophage function. By forming a complex with fatty acid synthase at 
peroxisomes, FAMIN promotes carbon flux through de novo lipogenesis (DNL) and drives 
high levels of fatty-acid oxidation (FAO) alongside high levels of glycolysis. As a 
consequence, FAMIN deficiency causes defects in DNL, FAO, reactive oxygen species 
production, inflammasome activation, endotoxin-response and bacterial clearance, thereby 
providing a plausible explanation to the observed disease phenotype in patients with the 
variants Ile254Val and Cys284Arg. 
In paper III, we found higher LACC1 expression in human immune-tissues and cells such as 
spleen, lymph nodes, monocytes/macrophages, DCs and neutrophils. In addition, FAMIN 
expression was shown to be regulated by peroxisome proliferator-activated receptor ligands. 
In paper IV, we identified a number of potential candidate biomarkers that may be followed 
up in validation experiments in independent IBD case-control cohorts. Of particular interest, 
FAMIN serum levels were found to differ between IBD patients and healthy controls, with 
lowest expression in CD patients. This parallels mouse and human data suggesting reduced 
FAMIN activity predisposes to disease. 
In summary, this thesis characterizes LACC1/FAMIN as a new major player in IBD 
pathophysiology, identifying novel biological pathways that may be amenable to modulation 
for therapeutic purposes, while at the same time providing preliminary data of potential 
exploitation for biomarkers delineation. 
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1 INFLAMMATORY BOWEL DISEASE 
Inflammatory bowel disease (IBD) consists of the two major subtypes Crohn’s disease (CD) 
and ulcerative colitis (UC), two chronic idiopathic and remittent inflammatory disorders of 
the gastrointestinal tract (GI tract) 1,2. The most common symptoms of IBD include 
abdominal pain, diarrhea, fever, weight loss, blood- and/or mucus-containing stool 3–5. CD 
and UC can occur at any age, but the peak incidence is during late adolescence and early 
adulthood 4,5.  
IBD affects around 2.5 million people of European ancestry and the incidence is increasing 
worldwide 6 (Figure 1). IBD can be considered as a disease of the West as it was previously 
uncommon in non-Western areas of the world. However, the incidence and prevalence of 
IBD is now increasing rapidly due to changes in diet, environment and social norms in 
industrialized countries 6,7. In fact, many recent studies have reported the increasing incidence 
of this “Western disease” in Asia, Middle East and even South America 8–14.  
 
 
 
 
 
 
 
 
Figure 1. The global prevalence of IBD in 2015. The highest prevalence is found in North America, Australia 
and parts of Europe. Reprinted by permission from Macmillan Publisher Ltd: Kaplan, G. G. The global burden 
of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 12, 720-727, copyright (2015) 7. 
 
IBD patients require life-long medication, hospitalizations, recurring sick-leaves, and surgical 
intervention and may acquire serious complications (such as colorectal cancer) 15. There is a 
dramatic reduction of life quality in IBD patients 16, which consequently results in a 
substantial economical burden both on the healthcare system and on society as a whole 6. 
Although the etiology of IBD is still unknown, these complex immunologically mediated 
diseases are believed to occur in genetically predisposed individuals due to a dysregulated 
immune response towards environmental triggers, gut microbiota and medication use 17,18. 
Therefore, it is of great importance to attempt to elucidate the etiology of IBD, with a view to 
find a more efficient therapeutic management of the disease and eventually a cure. 
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1.1 THE CLINICAL ENTITIES 
IBDs are heterogeneous inflammatory diseases where the inflammation can affect one 
specific area of the GI tract or several different areas simultaneously 1. UC is characterized by 
a continuous inflammation of the intestinal mucosa (Figure 2) and it is limited to the 
colon/rectum while CD manifests with transmural inflammation involving eventually all the 
intestinal wall layers and can affect different part of the GI tract in a segmented/patchy 
distribution. Generally, IBD is divided into three different phenotypes, namely CD, UC and 
indeterminate colitis (IC) 19,20. The two main phenotypes, CD and UC, have several 
overlapping clinical and pathological features, but they can still be distinguished from one 
another by localization, endoscopic appearance, histology and behavior 4,5. In cases where it 
is difficult to distinguish CD from UC using the diagnostic criteria, the condition is called IC 
19,20. During the past years, there have been several classification systems suggested for the 
identification of these phenotypic subgroups 21–23.  
Figure 2.  Endoscopic images of healthy colon (left) and severe ulcerative colitis (right). By courtesy of CH, 
endoscopist at Gastrocentrum, Karolinska University Hospital, Stockholm, Sweden. 
The Montréal classification was introduced as a revised version of the previous ones and for 
the first time the Montréal Working Party recommended a sub-classification system for UC 
4,5,23. The Montréal classification system was the result of a gathering of experts in 2003, to 
establish an integrated clinical, molecular and serological classification of IBD 24. The result 
of this gathering was presented at the 2005 Montréal World Congress of Gastroenterology 23. 
1.1.1 Crohn’s disease 
In 1932, articles were published by the three physicians Dr. Burrill Crohn, Dr. Leon Ginzburg 
and Dr. Gordon Oppenheimer, where they described a condition causing inflammation in the 
terminal ileum 25,26. At the start, this condition was termed regional or terminal ileitis, but 
later on the entity was referred as Crohn’s disease 25. CD is a lifelong chronic relapsing 
immune-mediated disease with unknown etiology 27.  The diagnosis is based on clinical 
history and physical examination in combination with endoscopic, histological and 
radiological findings 27,28. The Montréal classification of CD has 3 main parts, age at 
diagnosis, disease location and behavior to differentiate patients into useful clinical categories 
(Table 1 and Figure 3A). The inflammation in CD is patchy and can involve any part of the 
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GI tract from the mouth to the anus, but most commonly involves the distal ileum and colon 
1,29. A recent large genotype association study showed that predictive models based on 
genetic risk scores could actually distinguish between iliac and colonic CD (iCD and cCD). 
Thus it has been suggested that CD should be subdivided, on the base of genetic factors, into 
iCD an cCD 30. The clinical features of CD differ according to disease location and include 
chronic diarrhea with or without blood and mucus, weight loss, fever and abdominal pain. 
Disease location is a fundamental feature of CD (Table 1 and Figure 3A), and it is in part 
determined by genetic susceptibility. It is also the major driver of change in disease behavior 
over time 30. Patients can also display different extraintestinal manifestations such as 
aphthous mouth ulcers, skin ulcers called pyoderma gangrenosum and inflammation of fat 
cells under the skin, a condition known as erythema nodosum 27,31 (Figure 3B). The course of 
CD consists typically of relapse and remission periods with repeated phases of inflammation 
that are followed by the development of strictures, abscesses and fistulas 32.  CD can occur at 
any age but most frequently the diagnosis is made in patients in their 20s 32. CD diagnosis at 
an earlier stage of life (<40 years) has usually a more aggressive prognosis than a diagnosis 
later in life (>40 years) 33,34. Early-onset CD (EOCD) is often monogenic and associated with 
a severe phenotype 35–37.  
Table 1. Montréal classification for Crohn's disease 4,23 
 
Table 2. Montréal classification for extent and severity 
of ulcerative colitis 5,23 
   Crohn's disease 
 
Ulcerative colitis 
Age at diagnosis A1 below 16 years 
 
Extent   Anatomy 
 A2 between 17 and 40 years 
 
E1 Ulcerative 
proctitis 
Involvement limited to 
rectum  A3 above 40 years 
 
 
Location L1 ileal 
 
E2 Left sided 
UC (distal 
UC) 
Involvement limited to a 
proportion of the 
colorectum distal to the 
splenic flexure 
 L2 colonic 
 
 
 L3 ileocolonic 
 
 
 L4 isolated upper disease* 
 
E3 Extensive 
UC 
(pancolitis) 
Involvement extends 
proximal to the splenic 
flexure Behavior B1 non-stricturing, non-penetrating 
 
 
 B2 stricturing 
 
  
 B3 penetrating 
 
Severity   Definition 
  p perianal disease modifier 
 
S0 Clinical 
remission 
Asymptomatic 
* Can be added to L1-L3                                                                         
"p" is added to B1-B3 when concomitant perianal disease 
is present 
 
  
 
S1 Mild UC Passage of four or fewer 
stools/day (with or 
without blood), absence of 
any systemic illness, and 
normal inflammatory 
markers 
 
  
   
  
   
  
   
S2 Moderate UC Passage of more than four 
stools/day with minimal 
signs of systemic toxicity 
   
 
   
  
   
S3 Severe UC Passage of at least six 
bloody stools/day, pulse 
rate > 90 beats/min, 
temperature > 37.8 °C, 
haemoglobin < 10.5 g/dl, 
and ESR > 30 mm/h 
   
  
   
  
   
  
   
ESR, erythrocyte sedimentation rate. 
 4 
Figure 3*.  Phenotype of Crohn’s disease. (A) Montréal classification 23 by age is A1<16 years, A2 17-40 
years, A3>40 years. (B) Major extraintestinal manifestations and associated autoimmune disorders (blue). 
GI=gastrointestinal. p=perianal disease modifier. p is added to B1-3 when concomitant perianal disease is 
present. L4 describes upper GI disease and is also used as a modifier that can be added to L1-L3 when 
concomitant upper GI disease is present.  
1.1.2 Ulcerative colitis 
Clinical and pathological features of “ulcerative colitis-like” disorders have been described 
since Hippocrates (460-377 BC), but it was first in 1859 that the British physician Samuel 
Wilks identified UC as a distinct disease 38,39. UC is the more prevalent form of IBD and 
similar to CD in that it is a lifelong chronic inflammatory disease with unknown etiology 40. 
Some of the most common clinical features of UC include blood in the stool, chronic 
diarrhea, fever and abdominal pain 5. Montréal classification of UC considers the extent and 
severity of disease (Table 2). As for CD, the diagnosis of UC is made through a combination 
of medical history, physical examination as well as macroscopic, microscopic and endoscopic 
examinations. UC is characterized by inflammation that typically starts in the rectum and 
spreads proximally in a continuous fashion. However, the inflammation is limited to the 
colon. In contrast to CD where the inflammation can spread through all the intestinal wall 
layers, the inflammation in UC is only affecting the mucosal layer 4,5. Histologically, a 
varying degree of infiltration of immune cells, such as lymphocytes, plasma cells and 
granulocytes, can be seen in the mucosal layers 41–43. About 10% of the patients have 
extraintestinal manifestations, such as arthropathy, episcleritis and erythema nodosum 5. UC 
is characterized by periods of relapse and remission. In the same manner as CD, UC may 
                                                
* This image was published in Lancet 380 by Baumgart D. and Sandborn W. Crohn’s disease, 1590-1605, 
copyright Elsevier 2012 27. 
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occur at any age but the diagnosis is more common in patients in their 30s 44. In addition, 
there is a second peak of disease onset between the ages of 50-70 years 40. Similar to CD, 
early onset of UC (before the age of 16) has often a more aggressive initial course 5. 
1.2 MANAGEMENT OF DISEASE 
There is as yet no definitive cure for IBD and therefore medical treatments are used to 
ameliorate the life quality of the patient and to achieve a sustained clinical and endoscopic 
remission 27. There are several crucial issues regarding the clinical management of IBD. 
Apart from the often significant delay until diagnosis, there is also a lack of tools to aid 
prediction of who will develop severe disease with complications and who will benefit from 
which therapy. There are a few promising faecal biomarkers, such as calprotectin, lactoferrin, 
elastase and S100 calcium binding protein A12 (S100A12), that are used as diagnostic tools 
and have been proven to detect inflammation of the colon 4,5,45. In a recent study, regular 
faecal calprotectin measurements have been shown to aid in predicting IBD relapse 46. It is 
important to note that calprotectin, just as the other biomarkers, detect inflammation in 
general. The majority of the biomarkers used today originate from neutrophils. Nonetheless, 
several studies have shown changes in eosinophil numbers, eosinophil protein release and 
extracellular deposits of eosinophil cationic protein (ECP) as well as elevated faecal ECP and 
eosinophil protein X (EPX) in UC 47–50. Taken together this indicates that eosinophil proteins 
might be novel biomarkers for UC. However, more studies are needed to determine the 
dynamics of UC activity and eosinophil response. 
The heterogeneity of the disease affects the clinical management of patients and requires a 
more personalized treatment in order to find a safe therapeutic approach that benefits the 
individual patient 51. Mild to moderate UC inflammation can be successfully treated with the 
anti-inflammatory 5-aminosalicylic acid (5ASA) compound with a quite safe tolerability 
profile 5. For moderate to severe inflammation steroids, orally or intravenously, remain so far 
the principal treatment both for UC and CD 4,5. In case of steroid-dependency and/or 
refractory disease and in case of very aggressive inflammation, immunosuppressive agents 
such as thiopurines and/or biological treatment (such as anti-TNFα) can be used 51,52. 
Unfortunately, none of the therapeutical strategies used today is free from severe side effects. 
In particular it has been shown that triple therapy with steroid, immunosuppressive and 
biologicals may give a higher risk of severe infections, while increased risk of malignancy 
has been observed for long-term therapy 51,52. Furthermore, surgery has a central role in the 
therapeutical strategy for IBD patients. It has to be carefully timed to optimize the condition 
of the patients before the operation and to decrease risk of complications. Tight collaboration 
between gastroenterologist and surgeon is highly recommended for optimization of IBD 
management 40,53.  
Overall, there is a need to improve the diagnostic criteria, identify predictors of disease 
course, and establish novel criteria for tailor‐made therapy in individual patients. Therefore, 
there is an urge for biomarker discovery in IBD. 
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1.3 PATHOGENETIC MECHANISMS IN IBD 
During the past 10-15 years several biological pathways have been shown to be involved in 
the pathogenesis of IBD. The discovery of these pathways was made mainly by the 
identification of disease-specific genes. The most extensively investigated pathways involve 
the innate and adaptive immunity, autophagy, the cytokine response and alterations of the gut 
microbiota composition 54,55 (Figure 4).  
 
 
 
 
 
 
 
 
 
 
Figure 4. Key pathways involved in the pathogenesis of disease, deriving from gene discovery in IBD. 
NOD2, ATG16L1, IRGM and IL23R focused the attention to microbial recognition, autophagy and adaptive 
immunity. These pathways are mainly associated with CD, whereas UC has been shown to be associated with 
epithelial barrier genes. Reproduced from New IBD genetics: common pathways with other diseases, Lees, C. 
W. et al., 60, 1739-1753, Gut copyright 2011 55 with permission from BMJ Publishing Group Ltd. 
1.3.1 Immune cells in IBD 
The immune system consists of innate and adaptive immunity, functions that protect the host 
from invading pathogens. The epithelial barrier together with the mucosal layer is the first 
line defense against the invaders. The activation of the innate immune cells such as antigen 
presenting cells, phagocytes and granulocytes in turn induces the initiation of the adaptive 
(memory) immunity 2,3. The innate immunity is non-specific and does not elicit long lasting 
immunity. The epithelial barrier, mucosal layer, neutrophils, monocytes, macrophages, 
dendritic cells (DCs), natural killer (NK) cells, eosinophils, basophils and the novel family of 
innate lymphoid cells 56 (ILCs; ILC1, ILC2 and ILC3) are the “building blocks” of the innate 
immune system 57. By interacting with each other, the innate immune cells start the 
inflammatory process through secretion of cytokines, chemokines and antimicrobial peptides. 
Additionally, this results in phagocytosis of infected cells and pathogens, antigen presentation 
and activation of the adaptive immunity 3. The adaptive immune system consists of cytokine 
producing T-cells and antibody producing B-cells 57. T-cells are divided into different 
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subtypes depending on the cytokines and transcription factors expressed. The major subtypes 
include T-helper (TH), T-regulatory and T-cytotoxic cells 58. In contrast to the innate 
immunity, the adaptive immunity response is specific and long lasting 2,3. Although T-cells 
and the adaptive immune system have a major role in IBD pathogenesis, they will not be 
discussed further here. Instead, in line with the subject of this thesis, the focus in the 
upcoming paragraphs will be on the innate immune cells; neutrophils, 
monocytes/macrophages and the recently IBD implicated ILCs (Figure 5). 
Figure 5. Immune cells and cytokines in the pathogenesis of IBD. In patients with IBD and in experimental 
mouse models of colitis, pro-inflammatory and anti-inflammatory cytokines have been shown to be produced by 
various cells of the mucosal immune system in response to environmental triggers. In particular, dendritic cells 
(DCs), neutrophils, macrophages, natural killer (NK) cells, intestinal epithelial cells (IECs), innate lymphoid 
cells (ILCs), mucosal effector T cells (TH1, TH2 and TH17) and regulatory T (TReg) cells produce cytokines in the 
inflamed mucosa. The key transcription factors and cytokines produced by T helper cell subsets in IBD-affected 
mucosa are shown. The balance between pro-inflammatory and anti-inflammatory cytokines regulates the 
development and potential perpetuation of inflammation in patients with IBD. The dashed arrow indicates that 
ILCs, which produce cytokines that are involved in intestinal inflammation, may respond to IL-18. GATA3, 
GATA-binding protein 3; IL, interleukin; RORγt, retinoic acid receptor-related orphan receptor-γt; TGFβ, 
transforming growth factor-β; TNF tumor necrosis factor. Reprinted by permission from Macmillan Publisher 
Ltd: Neurath, M. F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329–342 copyright (2014) 
59. 
1.3.1.1 Neutrophils 
Neutrophils are the most abundant polymorphonuclear leukocytes in human blood, generated 
nonstop in the bone marrow. The daily production may reach up to 2×1011 cells 60 under the 
control of  granulocyte colony stimulating factor (G-CSF) 61, produced in response to 
interleukin-17A (IL-17A). IL-17A is synthesized by T-helper 17 (TH17) cells that regulate the 
neutrophil production 62. Tissue-resident macrophages and DCs regulate the IL-17A release 
by secreting IL-23. During neutrophil maturation three types of granules are formed and 
filled with numerous pro-inflammatory proteins 60,63. Neutrophils are quickly recruited to 
infection sites, where they fulfill their antimicrobial duties (Figure 5). These immune cells 
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have a critical physiological function to kill pathogens through different mechanisms; 
phagocytosis, degranulation and by releasing neutrophil extracellular traps (NETs) 60. 
Neutrophils are able to recognize diverse pathogens through cell surface and intracellular 
receptors, such as Nod-like receptors (NLRs) and toll-like receptors (TLRs), and in this way 
activate pathways to eliminate the pathogens 64. When neutrophils have recognized and 
engulfed the pathogens in the so-called phagosome, they kill the pathogen by producing 
reactive oxygen species (ROS) or by secreting antibacterial proteins, such as cathepsins, 
defensins, lysozyme and lactoferrin 63,65. Neutrophils can also after recognition of pathogens 
simply secrete different antimicrobial proteins and proteases in order to eliminate them 60. 
These antimicrobial proteins can either be secreted into the phagosomes or to the extracellular 
sites where pathogens are in order to eliminate them. Lastly, upon activation neutrophils can 
secrete NETs that contains chromatin and granular proteins 66. These NETs capture the 
pathogens in their surroundings and immobilize them, which in turn prevents the spreading of 
the pathogens and simplifies their phagocytosis. After performing their function, the 
neutrophils send a “find me” signal to macrophages that can through a process called 
efferocytosis regulate the phagocytosis of apoptotic neutrophils and in this way efficiently 
resolve the inflammation. Efferocytosis decreases IL-23 and IL-17 production and diminishes 
G-CSF production 67. 
Infiltrating neutrophils play a major role in the pathogenesis of IBD and are found in 
significant portions in the intestinal wall of IBD patients 68. Calprotectin and lactoferrin, 
which are neutrophil-associated proteins, are found in faecal samples of IBD patients and are 
therefore commonly used as diagnostic and monitoring biomarkers of IBD 69. Recently, 
Kvedaraite et al. reported that tissue-infiltrating neutrophils are the main source of IL-23 in 
the colonic tissues of pediatric IBD patients 70. With the contribution of neutrophil activity to 
the pathogenesis of IBD and other inflammatory diseases it would be of considerable value to 
find targeted therapies capable of modulating neutrophil activity. 
1.3.1.2 Monocytes/Macrophages 
Produced in the bone marrow, monocytes are the mononuclear leukocytes that can mature 
into macrophages or DCs. Monocytes are abundant in the lymph nodes and spleen and when 
a pathogen enters the body, they migrate through the bloodstream to the infected site where 
they differentiate into tissue resident cells 71. Monocytes and their progeny have several 
functions in the immune system, such as antigen presentation (therefore called antigen 
presenting cells), regulation of tissue homeostasis and repair, phagocytosis, and cytokine 
production 71. Macrophages can also activate nitric oxide synthase, which in turn results in 
the production of nitric oxide. This gives macrophages cytostatic and cytotoxic activity 
against many extracellular and intracellular intruders, such as bacteria, fungi, helminthes, 
viruses and tumor cells 72. Macrophages are a very heterogeneous group of cells that can be 
divided into subgroups depending on the anatomical location and their function 71. M1 
(inflammatory) macrophages are a class of macrophages that are classically activated in order 
to protect the host from bacteria, viruses and have antitumor properties. M1 macrophages 
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have a metabolism that is characterized by increased glycolytic rate and reduced 
mitochondrial oxidative phosphorylation (fatty-acid oxidation; FAO) compared to un-
activated or alternatively activated macrophages, so called M0 and M2 macrophages 
respectively 73. M2 (regenerative) macrophages have anti-inflammatory properties and are 
involved in tissue homeostasis and repair 71,74. M2 macrophages have an oxidative 
metabolism for survival and to support the cell function 75,76.  
Inflammatory macrophages strongly regulate the pathogenesis of IBD by producing pro-
inflammatory cytokines such as IL-23 and tumor necrosis factor α (TNFα) 77,78 (Figure 5). It 
has been reported that CD and UC patients have increased expression of the pro-
inflammatory cytokine IL-17, which originates from T-lymphocytes and 
monocytes/macrophages 79. Although, there are extensive indications that macrophages have 
a pro-inflammatory role in inflammatory diseases, many studies have also shown the immune 
suppressive roles of these cells 74. Activated macrophages produce pro-inflammatory 
cytokines that have been shown to protect mice from CD by accelerating the clearance of 
pathogenic commensal bacteria from the mucosal layer of the bowel 80. The maintenance of 
homeostasis of the intestine is thought to be a result achieved by recruited monocytes and 
resident tissue macrophages, which clear the site of inflammation from apoptotic cells and 
debris, promotes epithelial repair, antagonizes pro-inflammatory macrophages and produces 
suppressive cytokines 80–82.  
Macrophages have also been shown to be highly elevated in adipose tissues in the lymph 
nodes and intestine of CD patients 83–86. These fat depots are called “creeping fat” or “foam 
cells” and have been found to have a protective role in CD by functioning as an enveloping 
barrier on the site of inflammation and in this way potentially limiting it. The macrophages 
have a M2 subtype in the creeping fat and secrete anti-inflammatory cytokines like IL-10, IL-
6 and TNFα 86. 
1.3.1.3 Innate lymphoid cells 
The ILCs resemble the TH1, TH2 and TH17 cells, with the exception that they are involved in 
the innate immunity and in tissue formation, repair and remodeling 87,88. Three key features 
define these novel effector cells: the absence of B- and T-cell antigen-specific receptors; the 
absence of ‘classical’ immune cell markers (besides some NK cell markers); and lastly their 
lymphoid morphology 89. The ILCs accumulate in the mucosal tissues and exert host 
protective immunity by secreting the same cytokines as their TH-cell counterparts (Figure 5). 
Just like TH1, ILC1 contributes to host resistance against intracellular infection 90. ILC2 
shares the TH2 activity against helminth invasion 91 and ILC3 contributes to host resistance 
against bacterial and fungal infections by secreting IL-17A and/or IL-22, like TH17 92,93. In 
mice models, ILCs have been shown to be the mediators of chronic intestinal inflammation 
94. Additionally, Geremia et al. found that cells isolated from inflamed colon of patients with 
CD or UC have increased expression of ILC3 cytokines, cytokine receptors and transcription 
factors 95. Further studies are warranted to elucidate the function of ILCs in IBD. 
 10 
1.3.2 IBD pathways 
There are a number of central pathways that have been discovered to be involved in IBD 
pathogenesis. These include bacterial recognition intracellular and transmembrane receptors, 
intracellular catabolic processes, cytokine signaling and host-bacteria interactions (Figure 6). 
Figure 6. Schematic representation of cell-specific signaling pathways mediated by CD susceptibility 
genes. The mucus layer and tight junctions associated with intestinal epithelial cells maintain barrier integrity 
under homeostatic conditions. Disruption of this balance between host-defense immune responses and enteric 
bacteria is central to the pathogenesis of CD. This figure illustrates signaling pathways involved in inflammation 
and the potential roles of proteins encoded by IBD disease-associated genes. DC, dendritic cell; MSP, 
macrophage-stimulating protein; MST1R, macrophage-stimulating 1 receptor (the MSP receptor); NO, nitric 
oxide; PTGER4, prostaglandin E receptor 4. Reprinted by permission from Macmillan Publisher Ltd: Xavier, R. 
J. & Rioux, J. D. Genome-wide association studies: a new window into immune-mediated diseases. Nat. Rev. 
Immunol. 8, 631–643 copyright (2008) 96. 
1.3.2.1 Nod-like and toll-like receptors 
The pattern-recognition receptors (PRRs) play an important role in IBD since it is crucial to 
distinguish external pathogens from the commensal gut microbiota 97. The innate immune 
system uses PRRs to sense the presence of microorganisms and thereafter activate an immune 
response toward potential infectious threats. When the PRRs detect pathogen-associated 
molecular patterns (PAMPs) they activate monocytes, macrophages, DCs and neutrophils in 
order to eliminate the infectious threat 97. PAMPs activate PPRs and lead to a downstream 
signaling cascade where pro-inflammatory cytokines are produced 98. Inflammasome 
activation is a consequence of immune responses toward pathogens. Inflammasomes are 
multiprotein oligomers, which upon activation recruit pro-caspase 1 that in turn induces 
autoproteolytic cleavage into active caspase-1. Caspase-1 cleaves pro-IL-1β and pro-IL-18, 
which leads to the generation of the biologically active IL-1β and IL-18. The exact 
composition of the inflammasome is dependent upon the response-triggering molecule. Most 
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inflammasomes are formed with NLR family members, a family of the PRRs 98. There are 
five families of PRRs but only two of them will be briefly described here. 
NLRs (also called leucine-rich repeat (LRR)-containing receptors) are cytosolic receptors that 
get activated through recognition of different intracellular pathogens 99. Nucleotide-binding 
oligomerization domain (NOD) proteins NOD1 and NOD2 are NLRs that are composed of a 
N-terminal with caspase activation and recruitment domain (CARD), a nucleotide-binding 
oligomerization domain (NOD), and a C-terminal with multiple ligand-binding LRRs 100,101. 
NOD1 gets activated by binding D-glutamyl-meso-diaminopimelic acid (iE-DAP), a dipeptide 
primarily found in Gram- bacteria but also in some Gram+ bacteria 102,103. In contrast, upon 
binding of muramyl dipeptide (MDP; peptidoglycan derived from gram+/- bacteria) NOD2 
undergoes an oligomerization, which in turn activates the adaptor receptor-interacting protein 
2 (RIP2). The activation of RIP2 starts a downstream signaling cascade that in the end results 
in the activation of the nuclear factor-κB (NF-κB) transcription factor 102,103. NF-κB belongs 
to an evolutionary conserved transcription factor family that regulates the induction of gene 
expression involved in inflammation and immune responses 104.  
TLRs are a class of PRRs with the highest expression on monocytes and neutrophils 71. TLRs 
are a family of at least 12 transmembrane PRRs characterized by an extracellular LRR 
domain, a transmembrane domain and a cytoplasmic Toll/IL-1 receptor (TIR) domain 105. 
The extracellular domain recognizes the bacterial ligand through the LRR-containing 
horseshoe-like structure. Upon ligand binding the TLRs form homo- or heterodimers, recruit 
adaptor proteins and signal through different pathways downstream in order to activate the 
NF-κB transcription factor and induce pro-inflammatory cytokine production by monocytes 
and macrophages 97. 
1.3.2.2 Autophagy 
The process of autophagy was described already in the early 1960s 106, and was initially 
considered to be an energy recycling pathway activated by nutrient deficiency. However, 
with the discovery of the association between autophagy and CD 107,108 there has been 
a renewed interest in the autophagy pathway and its role in innate immunity and 
inflammation. 
Autophagy is an evolutionary conserved intracellular catabolic process that delivers cellular 
components to the lysosome for degradation 109. There has been a rapid expansion of 
knowledge regarding the autophagy pathway over the last 20 years, driven by basic studies in 
yeast 110. These studies have aided in identifying important molecular components and 
regulators of this pathway.  
The process of autophagy involves a survival mechanism induced by external stimuli such as 
cellular starvation, stress or infection, in order to protect the organism 111. Thus, the 
autophagy pathway is induced when the cells need to eliminate damaging content such as 
bacteria, other pathogens and protein aggregate accumulations 111. In addition, autophagy 
occurs at low basal levels in virtually all cells in order to maintain cellular homeostasis 
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through protein and organelle turnover. This pathway is then rapidly upregulated when cells 
are in need of energy and nutrients, for instance during growth factor absence, starvation and 
high bioenergetic demands111. Furthermore, the autophagy pathway is involved in several 
different immune processes as it has been shown to be important for regulating self-renewal, 
maturation and survival of B cells, T cells and haematopoietic stem cells 112–115. The 
autophagy pathway is also essential for the monocyte maturation into macrophages 116. 
Thus, the upregulation of autophagy may facilitate proper regulation of innate immune 
signaling and enhancement of antigen presentation, in addition to enhancing pathogen 
degradation 111,117–119. Hence, autophagy plays an important role in immune function, tissue 
remodeling, and disease 111. 
The core machinery of autophagy consists of over 30 autophagy-related genes (ATGs) 120. 
Recent studies have shown that polymorphisms in ATGs, such as autophagy-related 16-like 1 
(ATG16L1), ATG5, immunity-related GTPase family M (IRGM), and NOD2, are associated 
with an increased risk of IBD 55,107,108. However, the role of autophagy in both IBD and 
innate immunity is complex.  In some contexts, autophagy may enhance innate immune 
responses, whereas in other contexts autophagy may prevent excessive and destructive innate 
immune responses. Therefore, it has been suggested that the role of autophagy is to balance 
the innate immune response in such a way that it remains adaptive rather than dysfunctional 
119. Thus, upregulation of autophagy may be useful in enhancing the antimicrobial innate 
immunity and at the same time preventing excessive inflammatory responses that may be 
damaging to the organism. In fact, one study has been performed where one CD patient was 
treated with sirolimus (rapamycin), which is an immunosuppressant, as a candidate therapy 
121. Sirolimus was used to treat the patient for 6 months, which resulted in great 
improvements of the symptoms and endoscopic appearance 121. Sirolimus is a drug that 
inhibits mammalian target of rapamycin (mTOR) and thereby prevents T-cell proliferation 
121. mTOR is a serine/threonine kinase that is the key for inhibiting autophagy and other 
signaling pathways that regulate autophagy induction 122,123. Taken together, this study 
implicates defects in the autophagy pathway as a pathogenic mechanism in IBD, and suggests 
that targeting the members of this pathway may provide novel therapeutic possibilities. 
1.3.2.3 The IL-23 pathway 
The revolutionary discovery of the involvement of the IL-23 pathway in IBD pathogenesis 
led to the development of several clinical trials, targeting different genes involved along the 
pathway. In fact, there are several genes that have been associated with IBD, all positioned 
along the IL-23 biological pathway. 
IL-23 is a cytokine involved in the recruitment and activation of different inflammatory cells 
essential for the induction of chronic inflammation and granuloma formation, both hallmarks 
of IBD 124. The IL-23 pathway, in combination with the IL-12 pathway (responsible for 
antimicrobial response to intracellular pathogens), compromise two important immunological 
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pathways in the regulation of innate and adaptive immunity 124. The main source of IL-23 in 
IBD patients is believed to be infiltrating neutrophils in the colon tissue 70.  
IL-12 is a heterodimer, formed by the IL-12p40 and the IL-12p35 subunits, that signals 
through the IL-12 receptor (IL12R). The IL12R also consists of two subunits, IL12Rβ1 and 
IL12Rβ2. Activation of the IL-12 pathway leads to phosphorylation of signal transducer and 
activator of transcription (STAT) family members 125, which in turn results in differentiation 
of naïve CD4+ T-cells into interferon (IFN)-γ-producing TH1 cells 126. The IL-23 membrane 
receptor complex is composed of the IL-23 receptor (IL23R) that binds the IL-12p19 subunit 
and the IL12Rβ1 that binds the IL-12p40 subunit. IL-23 binds to the IL23R, predominantly 
expressed on memory T-cells, T-cell clones, NK cell lines, and in low levels on myeloid 
derived cells, such as monocytes, macrophages and DCs 127. By forming a heterodimeric 
complex with IL12Rβ1 IL23R regulates the IL-17 producing TH17 cells 128,129. TH17 cells are 
important in the host defense against different bacterial and fungal infections, and are 
involved in the pathogenesis of IBD 130. 
1.3.3 Microbiota 
The intestinal bacterial flora, gut microbiota, has been shown to have a significant role in the 
immune homeostasis 131. As previously mentioned, IBD is a complex disease and the 
interplay of genetic, microbial and environmental factors results in a continuous activation of 
the mucosal immune and non-immune responses. In a healthy individual, the intestinal 
mucosa is in a state of controlled inflammation regulated by a fine-tuned balance of different 
T-cell populations 59,132–135. In contrast, in IBD there is an immunological imbalance of the 
intestinal mucosa, predominantly associated with the cells from the adaptive immune system 
that react to self-antigens, which leads to chronic inflammatory conditions in the patients. The 
GI tract is the main site of interface between the host immune system and microorganisms, 
both symbiotic and pathogenic. Gut symbiotic bacteria are beneficial for the host: they 
metabolize indigestible compounds, extract vital nutrients from food, defend against 
pathogen colonization and contribute to intestinal architecture development 136. In IBD there 
is an imbalance in the gut microbiota (so-called dysbiosis), specifically there is an increase in 
the proportion of pro-inflammatory microorganisms and a decrease in anti-inflammatory 
microorganisms 137. 
The main components of the gut microbiota consist of the two phyla: Firmicutes and 
Bacteroidetes, which together make up approximately 90% of the gut microbiota 137,138. 
There are some other less abundant phyla; Proteobacteria, Actinobacteria (Bifidobacterium), 
Fusobacteria, Cyanobacteria, and Verrucomicrobia. Reports have shown that IBD patients 
have altered gut microbiota, where healthy controls had a significantly higher bacterial 
diversity compared to IBD patients 139,140. Frank et al. showed that the abundance of 
Firmicutes Lachnospiraceae and Bacteroidetes is depleted in IBD patients; instead several 
other less abundant phyla are enriched in these patients 139. Dicksved et al. compared the gut 
microbiota of monozygotic twins with CD 140. They showed that the healthy twins had a more 
diverse gut microbiota composition compared to the diseased twins and that there are 
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differences in the composition of Bacteroidetes species in iCD twins compared to cCD and 
healthy twins 140. In a review on the role of bacteria in CD, Man et al. compiled results from 
several studies on microbiota composition in patients, showing that CD patients have a 
decrease in abundance of Firmicutes and an increased abundance in Bacteroidetes and 
Proteobacteria 141. The gut microbiota of UC patients with inactive disease has been shown 
to be closer to that of healthy individuals, thus there seems to be differences in the influence 
of faecal microbiota on the pathophysiology of UC compared to CD 142. 
Faecal microbiota transplantation (FMT) has been shown to be a promising treatment option 
in IBD. The goal of FMT is to restore/normalize the gut microbiota and its interaction with 
the immune system. There are conflicting results regarding FMT treatment. However, in a 
recent meta-analysis of FMT treatment in UC patients they reported clinical remission of 
30.4% with no difference in administration route or number of infusions 143. At present there 
are not enough data on FMT treatment in IBD and more studies are needed in order to 
establish it as a therapeutic option 143,144. However, some of the obtained FMT results are 
very promising and with more knowledge it might be possible to use the gut microbiota not 
only for treatment, but also for diagnostics and disease monitoring in IBD patients. 
1.4 GENES AND GENETICS IN IBD 
The hereditary component of IBD was recognized already in the early 20th century, and we 
know today that the greatest risk of developing IBD comes from having a relative suffering 
from the disease 145. IBD is familial in 5-10% of individuals while the remaining 90-95% 
have a sporadic form 146. Several studies have shown that a positive family history is more 
common in CD patients than in UC patients, and the risk to develop IBD is larger in first-
degree relatives, especially in siblings 145,147–150. In addition, twin-studies have revealed that 
the heritable component is stronger in CD compared to UC, where monozygotic twins show 
higher phenotypic concordance in CD patients (37%) compared to UC patients (10%) 151,152. 
The causative mechanisms of IBD remain elusive, however it has been demonstrated 
repeatedly that there is a strong genetic component, and with the recent development of 
molecular genetics there has been a tremendous progress in the field of IBD genetics. In total, 
163 IBD loci have been identified through analyses of Caucasian populations 54, and further 
meta-analyses including multi-ethnic cohorts, like Asian, Indian and Iranian, led to the 
identification of additional loci, bringing the current number of risk loci up to 200 153. These 
data support the concept that IBD is a genetically complex disease with a large number of 
genes involved in its pathogenesis 54,153. 
1.4.1 Genetic history of IBD 
The genetic component of IBD has been known for a long time. However, it was not until the 
advent of genome wide association studies (GWAS) that the identity of the IBD genes started 
to unravel and with it the understanding of the pathogenic pathways within IBD. In GWAS, 
allele frequencies of common variants are compared between unrelated cases and controls 
154,155. GWASs have been used to identify several thousands of loci associated with a large 
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number of diseases and physiological traits. They reveal associations between specific 
genomic loci and genetic traits or diseases via a panel of hundreds of thousands to a million 
markers, so-called single nucleotide polymorphisms (SNPs). These SNPs are designed to tag 
all known common variants in the human genome. A successful GWAS will result in the 
identification of one or more genetic variants within a locus, marked by the associated tag 
SNP, that has biological functions driving the observed association with the disease or trait of 
interest 154,155.  
The research field of IBD genetics began in the 1980s with association studies using 
functional candidate genes and focusing mainly on the HLA genes. Then in the late 1990s a 
number of linkage studies identified shared chromosomal regions on chromosomes 1, 3, 5, 6, 
12, 14, 16, and 19 – subsequently called IBD1-IBD9 156,157. Further characterization of these 
IBD loci led to the identification of several IBD susceptibility genes, such as NOD2 (also 
known as CARD15) within IBD1 100. 
It was in 2001 that two independent groups used positional clonal strategy and positional plus 
functional candidate gene approach to identify the first CD susceptibility gene, NOD2 100,101. 
Only four years later in 2005, Yamazaki and colleagues performed the first GWAS for CD 
and identified several SNPs in the Tumor Necrosis Factor Superfamily Member 15 
(TNFSF15) gene 158. The following year a second GWAS for CD was published, where the 
authors, in addition to confirming the NOD2 risk variants, identified risk variants in the 
receptor for pro-inflammatory cytokine IL-23, namely IL23R gene 159. Less than 6 months 
later another very important discovery was made, a non-synonymous SNP in the ATG16L1 
gene was found to be associated with CD 107. During the last 10 years, there has been 
recognition of the fact that larger data sets are needed to find susceptibility alleles that might 
have only a small or modest contribution to IBD. In order to obtain these large data sets 
several national and international consortia have been formed, such as for example the 
International Inflammatory Bowel Disease Genetics Consortia (IIBDGC) 160, a world-wide 
collaboration project with the aim to collect very large datasets from many different 
countries. The meta-analysis studies resulting from this international collaboration have 
yielded a vast amount of knowledge on new susceptibility loci, common pathways and 
genetic differences between UC and CD 54,153,161–164. 
The identified IBD susceptibility genes have been shown to be part of several different 
molecular and cellular pathways in addition to being altered during the course of the disease. 
These pathways involve alterations of gut microbiota composition homeostasis, defects in the 
receptors of innate immune response toward pathogens, genes involved in autophagy and in 
the cytokine response.  Indeed, GWAS have paved the way for identifying the majority of 
presently known IBD risk genes and have advanced our awareness of the significance of 
genetic susceptibility in IBD. Nonetheless, these identified loci explain only a minority of the 
variance in CD (13.1%) and UC (8.2%)153 leaving a large number of discoveries to be made 
in future studies. Rare variants in monogenic IBD (100% penetrance) have large effect on 
gene function and are often not detected in GWAS 165. The innovation of next generation 
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sequencing has opened up new possibilities in the field of IBD genetics, with independent 
rare variants being discovered by deep re-sequencing of GWAS’s loci 166,167. Exploiting of 
this new technology will without doubt aid in discovering additional susceptibility genes, new 
gene variants and novel pathways important for IBD pathogenesis. 
1.4.2 Susceptibility genes in IBD 
A number of familial IBD loci have been identified through family studies using 
nonparametric linkage analysis. Some of these IBD loci have been replicated and confirmed 
by several GWAS. Through these GWAS it has been confirmed that several immune-
mediated diseases share many features 54,168. Although many of the identified risk loci are 
shared between multiple immune-mediated diseases, the pattern of genetic associations with 
the phenotypes varies. Candidate gene studies have supported the idea of shared susceptibility 
loci. Historically, the human leukocyte antigen (HLA) region has been implicated in immune-
mediated disorders 169, but more and more genetic loci located outside the HLA region are 
being described 170–172. On the basis of these observations, it is highly likely that subgroups of 
immune-mediated diseases share etiology and underlying mechanisms.  
As mentioned earlier, the two types of IBD, CD and UC, differ in several ways. Perhaps the 
most striking difference being the fact that CD has a higher family inheritance 145,147–150 
indicating a difference in the genetic background of the two. However, the clustering of these 
diseases in certain families and their somewhat overlapping risk loci (70%) also support 
similarities in their etiology 55,168. 
1.4.2.1 NOD2 
Hugot et al. and Ogura et al. identified the three major CD associated NOD2 mutations, 
Arg702Trp, Gly908Arg and Leu1007fsinsC (frameshift variant). All these mutations lie 
either within or near the C-terminal LRR domain, which is important for microbial sensing 
100,101. These mutations in the LRR domain lead to a decreased capacity to respond to bacteria 
and therefore impaired clearance of invading bacteria, which in turn may lead to a more 
severe inflammation since the anti-inflammatory pathway is not activated. Furthermore, as 
mentioned earlier, it has been shown that NOD2 initiates autophagy by recruiting ATG16L1 
to the plasma membrane at the site of bacteria entry. Thus, mutations in NOD2 do not only 
result in defective bacterial handling and antigen presentation but also in defective autophagy 
173,174. 
Interestingly, the CD susceptibility loci in NOD2 has been found to have a significant 
protective effect for UC 54, but the mechanism regarding how this susceptibility allele for CD 
is a protective allele for UC remains unclear. 
NOD2 can, independently of its role in NF-κB activation, also regulate autophagy through 
intracellular bacterial sensing 175. MDP activation of NOD2 in epithelial cells induces 
autophagy and increases the bacterial killing in an NOD2-dependent (and ATG16L1-
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dependent) manner, a signaling pathway that is defective in CD patients with the NOD2 
variants 176. 
1.4.2.2 TNFSF15 
After the NOD2 discoveries, several SNPs in the TNFSF15 gene were identified to be 
associated with CD 158. TNFSF15 gene encodes TNF ligand-related molecule 1A (TL1A), 
which binds to activated CD4+ T-cells and in this way induces the proliferation and 
differentiation of TH17-cells. These cells in turn produce IFNγ and IL-17, which are 
important cytokines in the defense against pathogens and in the homeostatic interaction with 
gut microbiota 177. Therefore, alterations in the TL1A signaling or expression affects the 
response to pathogens. Additionally, polymorphisms in the TNFSF15 gene may contribute to 
altered TL1A production, leading to pathogenesis of other inflammatory diseases. 
1.4.2.3 IL23R 
Various GWAS have identified several protective alleles for IBD that are associated with 
IL23R, namely Arg86Gln, Gly149Arg, Arg381Gln and Val362Ile 159,166,178. These protective 
alleles all have loss of activity, which results in reduced cell surface expression of mature 
IL23R and consequently reduced IL-23 signaling 179. In turn reduced IL-23 signaling leads to 
reduction in pro-inflammatory cytokines. The IL-23 pathway has been of specific interest due 
to the recent development of IBD antibody based therapies directed against IL23R or IL-
12p40, a subunit of both IL-23 and IL-12 180, with the aim to neutralize the IL-23 
pathway127,180. 
1.4.2.4 ATG16L1, ATG5 and IRGM 
Several GWAS have identified variants in the autophagy gene ATG16L1 to be strongly 
associated with CD 107,108,173,174,181,182, and variants in the IRGM gene to be associated with 
both CD and UC 54,181,183,184. ATG16L1 mediated interaction between ATG5 and ATG12 
leads to complex formation. This complex is then delivered to autophagosomes leading to 
breakdown of the bacteria and the bacterial antigen presentation 185. Autophagy may control 
inflammation through several different processes, such as interactions with innate immune 
signaling pathways, by removing inflammasome agonists and by affecting the cytokine 
secretion. 
1.4.2.5 PTPN22 
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is an enzyme involved in 
several signaling pathways. PTPN22 gene encodes the lymphoid tyrosine phosphatase (LYP), 
which is an important negative regulator of T-cell receptor signaling by de-phosphorylation 
of tyrosine residues from target proteins, and tyrosine phosphorylation has been shown to be 
important in the regulation of neutrophil function 186. PTPN22 is a gene that is altered in IBD, 
where the Arg620Trp variant is protective against CD 164,187. 
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1.4.3 The overlap of IBD with other immune-related diseases 
A major feature of the genetic architecture of IBD, both CD and UC, is the percentage (70%) 
of risk loci that are shared between these two subtypes. With the increasing numbers of 
GWAS performed for different diseases, it has become evident that there are a large number 
of susceptibility genes that overlap not only between different complex diseases, but also 
between complex diseases and monogenic diseases. Particularly interesting is the overlap of 
IBD risk loci with several genes conveying susceptibility to mycobacterial diseases such as 
leprosy 54,162,188–192. 
Susceptibility loci are shared between IBD and many other well-known immune-mediated 
diseases such as ankylosing spondylitis (AS), type 1 diabetes (T1D), celiac disease (CeD), 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, multiple sclerosis 
(MS) and juvenile idiopathic arthritis (JIA) 55,161,162,193–196 (Figure 7). The overlap between 
IBD and these immune-related diseases are through a number of different susceptibility genes 
such as HLA, IL23R and TNFSF15 for AS 159,164,197–199; HLA for CeD 55; Laccase 
(multicopper oxidoreductase) domain-containing 1 (LACC1) and PTPN22 for JIA 200–206; 
IL2RA, IL7R and PTPN22 for MS 55,161,197,207,208; IL23R, IL12β and PTPN22 for psoriasis 
55,209; PTPN22 and TNFSF15 for RA210–212; ATG5, IL-10 and PTPN22 for SLE 55,213; IL-10 
and PTPN22 for T1D 55,214,215. Interestingly, a PTPN22 variant (Arg620Trp) has been shown 
to be both a protective gene in CD 164 and a risk gene in SLE 216. In a similar fashion, variants 
of the gene TNFSF15 have been shown to be risk factors in CD and protective in leprosy 217. 
These observations add complexity to the genetics of immune-related diseases and emphasize 
the need for more knowledge on susceptibility gene function in different contexts. 
Nevertheless, the vast overlap of susceptibility genes point to shared biological mechanisms 
and pathways between many of the different immune-related diseases, for example when it 
comes to response to bacterial infections and inflammation. 
Leprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae (M. 
leprae) that causes nerve damage in the host 218. Leprosy is of particular interest since there is 
a very strong genetic overlap with IBD. There are only a few genes identified for leprosy so 
far and all of these genes are in fact also IBD associated genes. The shared genes between the 
two diseases include NOD2, TNFSF15, RIP2, LRRK2, IL23R, IRGM and LACC1, which are 
all confirmed IBD/leprosy genes in a number of cohorts 54,162,164,181,188–192. Both leprosy and 
CD have granuloma formation as a clinical feature 41,218 and mycobacterial infection has been 
implicated in CD as a causative factor 219,220. IL12β is confirmed as a known susceptibility 
gene for mycobacterial infection in CD and leprosy 161,221. Additionally, the known CD and 
leprosy susceptibility genes, NOD2, RIP2 and IRGM, may cause deficiency of mycobacterial 
recognition and clearance through autophagy. Therefore, despite the fact that CD and leprosy 
are different clinical entities, they are both chronic inflammatory diseases and there is 
indicative evidence that these two diseases share common pathogenic mechanisms.  
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Figure 7. Schematic presentation of susceptibility gene-overlap between IBD and other immune-related 
diseases. The susceptibility genes given in the figure is a selection, more genes have been described in the 
literature. Grey lines indicate existence of overlap in susceptibility genes between the connected diseases, 
however these genes are not the focus here. AS: Ankylosing spondylitis; CeD: celiac disease; JIA: juvenile 
idiopathic arthritis; MS: multiple sclerosis; IBD: inflammatory bowel disease; RA: rheumatoid arthritis; SLE: 
systemic lupus erythematosus; and T1D: type-1 diabetes mellitus. 
JIA is a chronic inflammatory childhood arthropathy, with enduring joint damage and lasting 
functional limitations and disabilities 222. There is significant evidence for genetic 
involvement behind this complex disease. JIA has a lot in common with other immune-
related diseases like RA and also IBD.  One gene previously implicated in JIA is PTPN22, 
that is associated with increased risk of different phenotypes of JIA in different populations 
200–205. Recently, a rare missense mutation in LACC1, a prototypic IBD gene of 
uncharacterized function, was found in a monogenic form of systemic JIA (sJIA) 206. LACC1 
is an example of a gene causing more than one immune-related disease. Remarkably, the 
same rare missense mutation was also detected in EOCD 37. The fact that LACC1 common 
variants are associated with both IBD and leprosy, whereas its rare variant is causative in both 
sJIA and EOCD implies that LACC1 is a major candidate gene for regulation of key immune 
functions. 
1.5 LACCASE (MULTICOPPER OXIDOREDUCTASE) DOMAIN-CONTAINING 1 
For more than a decade our research lab has been working at the genetic and functional 
characterization of IBD susceptibility genes. Recently, we focused considerable research 
efforts on the LACC1 gene. This was identified by GWAS as a CD risk gene already in 2008 
164 and it has surfaced as a particularly interesting candidate gene with potential to reveal 
novel pathways in IBD pathophysiology. 
LACC1, previously named Chromosome 13 open reading frame 31 (C13orf31), encodes a 
protein that lacks homology with any known mammalian protein. LACC1 is located on 
chromosome 13 (13q14.11) and contains 7 exons. The encoded protein consists of 430 amino 
acids and has a molecular weight of approximately 48 kDa. The LACC1 protein is unique in 
that it contains a laccase domain, which is similar to bacterial multi-copper polyphenol 
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oxidoreductases (POs, also known as laccases). Laccases are enzymes that catalyze the 
oxidation of a broad range of aromatic and phenolic substrates 223. These enzymes have also 
been shown to be the key components of the insect immune system 224. The conserved 
laccase domain is located in the C-terminal of the human LACC1 protein (Figure 8). 
Furthermore, computational gene function prediction identified phospholipid binding (24%) 
and lipid binding (20%) properties as the most significant molecular functions. 
Figure 8. LACC1 gene structure. LACC1 has a size of 14.650 bases and consists of 7 exons (yellow). The 
introns are indicated by black lines and the exons encoding the laccase domain are in red. 5’ and 3’ UTRs are 
given in purple. 
*************************** 
 
IBD has a strong genetic component and despite the increasing number of susceptibility 
loci/genes identified, our knowledge of disease pathogenetic mechanisms is still limited. The 
genes that have been found to be associated with IBD are all part of different pathways, such 
as microbial sensing (NOD2) 225, T-cell immunity (IL23R) 159 and clearance of pathogens 
through autophagy (ATG16L1, IRGM) 107,183. Polymorphisms in some of these genes have 
been reported to be associated with changes in gut microbiota composition and this 
emphasizes the link between microorganisms and inflammation in IBD 226,227. The IL23R and 
NOD2 may be of particular importance, since they appear to explain the largest fractions of 
genetic variance 54. Although as yet, it is not recommended to test for genetic variants in IBD 
for clinical purposes, the increasing knowledge of IBD susceptibility genes and their function 
will most certainly contribute to the individualization of IBD therapy in the not too distant 
future. In addition, the need for better diagnosis and the possibility to predict disease course is 
most eagerly anticipated. This may be achieved with the identification of well-characterized 
biomarkers and the characterization of the genetic background in different individuals. 
Possibly, the characterization of novel IBD susceptibility genes, such as LACC1, with 
hitherto unknown function, may lead to discoveries of pathogenetic pathways that can be 
translated into the clinic. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis is to characterize the novel LACC1 gene, and to understand its 
role in IBD and other inflammatory diseases. This thesis is based on the results generated in 
the four papers below, which will be discussed and referred to as paper I-IV throughout the 
thesis. 
The specific aim for each paper is: 
 
Paper I. To test the hypothesis that LACC1 common SNPs, in addition to CD, are associated 
with UC (the other major form of IBD), and non-systemic JIA (nsJIA). 
 
Paper II. To investigate LACC1 biological function, its role in immunity and inflammation.   
 
Paper III. To characterize LACC1 expression and subcellular localization in human primary 
cells, cell lines and tissues. 
 
Paper IV. To screen the IBD risk proteome in IBD patients and controls, in order to identify 
serum candidate targets for future IBD biomarker-profiling efforts. 
 
  
 22 
  
  23 
3 RESULTS AND DISCUSSION 
This section briefly summarizes the main findings of the thesis, and their interpretation. 
Detailed information can be found in papers I-IV. 
3.1 PAPER I: LACC1 COMMON POLYMORPHISMS ARE ASSOCIATED WITH 
UC AND JIA 
At the initiation of this study, the biological function of LACC1 was unknown. Nevertheless, 
it had been shown in previous studies that LACC1 common polymorphisms were associated 
with CD, leprosy and possibly UC 54,162,164,181,188–192,228. More recent evidence revealed that a 
rare LACC1 missense mutation (Cys284Arg) can cause monogenic forms of both EOCD and 
sJIA 37,206. While the relevance of LACC1 in IBD (CD) was known, the link to sJIA was 
novel, and prompted us to explore whether LACC1 common SNPs are associated also with 
the complex nsJIA form. For the purpose of the target candidate gene investigation, we 
genotyped 11 SNPs (selected based on their functional (coding variants) and tagging 
properties; Figure 9) and tested their effect on disease risk in 3855 Swedish individuals, 
including 1124 CD patients, 1297 UC patients, 229 nsJIA patients and 1205 healthy controls. 
Figure 9. Linkage disequilibrium map and characteristics of the studied LACC1 SNPs.  
Left: Linkage disequilibrium structure generated with Haploview 4.2 analysis of genotyping data from the 
control population. The numbers in each box correspond to r2-values between SNPs. Center: SNPs (Marker) and 
SNP position (Chr pos (Hg19)) are listed with alleles at each locus (SNP, minor allele in lower case) and minor 
allele frequency (MAF) in the European population was retrieved from Ensembl. Right:  position of each SNP 
within the LACC1 genomic region, and corresponding effect on messenger RNA (mRNA). Reprinted by 
permission from Macmillan Publisher Ltd: Assadi G. et al. LACC1 polymorphisms in inflammatory bowel 
disease and juvenile idiopathic arthritis, Genes Immun. 17, 261-264 copyright (2016) 229. 
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Variants of LACC1 are associated with increased risk of IBD, CD, UC and nsJIA 
In paper I, we described significant associations of the LACC1 variants with CD, UC, IBD 
and nsJIA. Significant association with CD was detected for eight SNPs, which were also 
significantly associated with increased risk of IBD. Six SNPs showed significant association 
with increased risk of UC in our Swedish cohort. Most notably, seven out of the eleven 
selected SNPs were found significantly associated also with an increased risk of nsJIA. The 
direction of the genetic risk effects was the same for CD, UC and nsJIA, indicating that 
similar pathogenetic mechanisms likely involve LACC1 polymorphisms in the predisposition 
to these conditions. 
In conclusion, we detected false discovery rate corrected significant associations with 
individual markers in the studied cohorts, thereby expanding previous results for CD to both 
UC and nsJIA. This is the first study showing that LACC1 polymorphisms are significantly 
associated with increased risk of nsJIA, and future studies are warranted to validate our 
findings in larger cohorts. The findings in paper I add to previous studies that showed the 
association of LACC1 variants with CD, EOCD, sJIA, leprosy and possibly UC 
37,54,162,164,181,188–192,206,228, thereby justifying further investigation into the role of LACC1 in 
immune-related diseases. These data are in line with evidence that common molecular 
mechanisms and pathways are involved in the pathophysiology of these diseases, which only 
share some of their clinical features. The overlap of several susceptibility loci among 
inflammatory diseases has aided in the understanding of various pathophysiological 
mechanisms, and therefore the characterization of LACC1 molecular function has the 
potential to shed new light upon the pathogenesis of IBD. While the characterization of 
LACC1 function is the scope of the following papers II and III, future detailed molecular 
analyses are warranted to decipher the precise mechanism(s) by which LACC1 SNPs affect 
the expression or function of the corresponding protein (FAMIN; the LACC1 encoded 
protein), thereby ultimately affecting risk of several diseases. 
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3.2 PAPER II: IDENTIFICATION OF FAMIN AS A MACROPHAGE METABOLIC 
REGULATOR  
From previous studies, LACC1 has been confirmed as a susceptibility gene for both IBD and 
leprosy, two diseases where the immune response to bacteria is key to the pathogenesis 
54,162,164,181,188–192,228–230. It has been shown that LACC1 is highly expressed in macrophages 
231, the immune cells that defend the host from both extracellular and intracellular bacteria. In 
paper II, we aimed at a functional characterization of LACC1 using in vivo and in vitro 
model systems. At the same time, we investigated the potential mechanisms by which LACC1 
causative coding variants affect disease risk. Throughout paper II we have chosen to refer to 
the LACC1/C13orf31 encoded protein as FAMIN (fatty acid metabolism-immunity nexus) 
due to our findings regarding its biological function(s). 
FAMIN co-localizes with peroxisome markers and interacts with fatty acid synthase 
Using confocal microscopy, we could show co-localization of FAMIN with the peroxisome 
markers 70-kDa peroxisomal membrane protein (PMP70) and catalase in macrophages, and 
this co-localization was further confirmed with proximity ligation assay (PLA) 232. In order to 
find FAMIN-interacting proteins, we performed an in vitro (immunoprecipitation) protein-
protein interaction screen, where we identified fatty acid synthase (FASN) as a FAMIN 
binding partner. The interaction between FAMIN and FASN was also detectable in 
macrophages using in situ PLA (Figure 10). FASN is a cytoplasmic protein that associates 
with the membranes of different subcellular compartments. FASN is important for de novo 
lipogenesis (DNL) 233 where it catalyzes the synthesis of long chain saturated fatty acids 
(LCFAs) from acetyl-CoA, malonyl-CoA and nicotinamide adenine dinucleotide phosphate 
(NADPH) 234. It has been shown previously that FASN co-localizes with PMP70 235. Thus, in 
macrophages FAMIN is localized to the peroxisome where it interacts with FASN. 
Figure 10. FAMIN interacts with FASN and localizes to peroxisomes. Proximity ligation assay of FAMIN 
and FASN (yellow) in THP-1 derived macrophages. The nucleus is stained with DAPI (blue). Scale bars, 5 µm. 
Reprinted by permission from Macmillan Publisher Ltd: Cader, M. Z. et al. C13orf31 (FAMIN) is a central 
regulator of immunometabolic function. Nat. Immunol. 17, 1046-1056 copyright (2016) 236. 
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FAMIN is a regulator of metabolic function and bioenergetic state in macrophages  
Since FAMIN interacts with FASN on peroxisomes, we hypothesized that FAMIN could 
affect FASN-dependent cellular functions such as DNL 237. To investigate the function of 
FAMIN we generated knockout Lacc1 (the mouse homologue of human LACC1) mice 
(mFamin-/-) and studied the effects of FAMIN absence on macrophages. In brief, 
macrophages from mFamin-/- mice differed from wild type (wt) in i) lower availability of 
fatty-acyl-CoA for FAO (also known as β-oxidation), ii) higher extracellular levels of citrate 
(indicating defective DNL), iii) less oxidative capacity, iv) lower levels of total cellular ATP 
and phosphocreatine. Hence, we concluded that in macrophages FAMIN functions as a 
regulator of i) synthesis of endogenous fatty acids (through DNL) and ii) mitochondrial 
oxidation. Likewise, FAMIN also controls glycolytic activity and overall ATP regeneration, 
and in doing so affects cellular energy availability in macrophages. Thus, FAMIN is localized 
to the peroxisome where it interacts with FASN, influencing macrophage cellular metabolic 
pathways  (Figure 11). 
Figure 11.  Schematic 
illustration of the cellular 
metabolic pathways showing 
FAMIN and FASN co-
localization at the peroxisome 
and their putative 
involvement in fatty acid 
metabolism. ACLY: ATP 
citrate lyase; CPT1a: carnitine 
palmitoyltransferase-1a. 
Reprinted by permission from 
Macmillan Publisher Ltd: 
Cader, M. Z. et al. C13orf31 
(FAMIN) is a central regulator 
of immunometabolic function. 
Nat. Immunol. 17, 1046-1056 
copyright (2016) 236. 
FAMIN knockout macrophages have defective clearance of bacteria  
With the observed effect of FAMIN absence on macrophage metabolism, we then 
investigated macrophage immunological function under the same (knockout) conditions, and 
observed inefficient intracellular bacterial killing in mFamin-/- macrophages. The same 
decrease in intracellular bacterial killing was seen in human macrophages, where FAMIN had 
been silenced using siRNA targeting LACC1 mRNA. ROS are important for macrophage 
bacterial killing, and in fact mitochondrial oxidation is crucial for the generation of ROS 238. 
In line with previous mFamin-/- data and mitochondrial activity, we observed a significant 
decrease in ROS content in mFamin-/- macrophages. Furthermore, there was a decrease in 
inflammasome activation in mFamin-/- macrophages when stimulated with lipopolysaccharide 
(LPS). This implies that full inflammasome activation in macrophages may be FAMIN-
dependent and requires FAO. Inflammasomes are the immune system sensors that induce 
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inflammation and sepsis 239, and in mFamin-/- mice injected with LPS sepsis profiles were 
significantly more pronounced. Taken together, the in vivo experiments confirmed the 
importance of FAMIN for bactericidal and inflammasome function in macrophages.  
LACC1 coding variants impair FAMIN function 
Two LACC1 coding variants have been reported in association with disease, namely the 
common Ile254Val (rs3764147G/G) variant is increased in CD patients compared to controls, 
while the rare Cys284Arg variant has been found in familial cases of EOCD and sJIA. To 
investigate the potential effects of LACC1 coding variants on FAMIN function we used the 
CRISPR-Cas9 gene-editing system on wild type C57BL/6N mice. Wild type C57BL/6N 
mice carry the mFaminp254Val variant with a valine at position 254 that corresponds to the 
human CD and leprosy risk variant rs3764147G/G. We generated mice homozygous for i) the 
p254Ile (CD and leprosy non-risk variant, rs3764147A/A) with a substitution of isoleucine for 
valine at position 254 (mFaminp254Ile) ii) the rare missense mutation at amino acid position 
284 changing a conserved cysteine into an arginine (mFaminp284Arg, p284Arg).  
In summary, mFaminp254Ile macrophages displayed the highest glycolysation rate, basal 
oxygen consumption rate (OCR), maximal uncontrolled-OCR and extracellular ROS (eROS), 
whereas mFaminp254Val had intermediate levels of all these. The mFaminp284Arg macrophages 
had the lowest metabolic flux and showed diminished levels of eROS, comparable with the 
mFamin-/- macrophages. Moreover, we studied macrophages and neutrophils from healthy 
human donors carrying either the risk haplotype p254Val or the non-risk haplotype p254Ile. 
Isolated p254Val human macrophages had lower extracellular ROS (eROS) production 
compared to p254Ile, confirming the results from the mouse macrophage studies. Isolated 
human neutrophils showed a similar pattern as the macrophages, extending FAMIN 
importance to neutrophil function as well. All together, these results imply that p254Val leads 
to partial loss and p284Arg to a complete loss of FAMIN function, thus linking diminished or 
lack of FAMIN biological activity to disease predisposition.  
To summarize paper II, we identify FAMIN as a core metabolic regulator of macrophage 
function. FAMIN forms a complex with FASN at peroxisomes and promotes carbon flux 
through DNL, and drives high levels of FAO alongside with high levels of glycolysis. As a 
consequence, FAMIN deficiency causes defects in DNL, FAO, ROS production, 
inflammasome activation, endotoxin-response and bacterial clearance. 
The discovered critical role of FAMIN and FAO for macrophage function adds a metabolic 
pathway to the various pathways already implicated in immune-related diseases. Metabolic 
pathways have recently emerged as important determinants of immunological function 75. It 
has been long known that macrophage adhesion and phagocytosis can be affected by the ratio 
of saturated and unsaturated fatty acids 240, possibly through the effects of fatty acids on the 
macrophage cell membrane 241. More recently, it has been shown that inhibition of the 
mitochondrial citrate carrier (CIC/SLC25A1), a protein essential for both FAO, macrophage 
activation and inflammatory responses 242,243, causes citrate to accumulate within 
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mitochondria thereby leading to both reduced ROS and reduced prostaglandin production in 
macrophages 229. Citrate plays an important role in fatty acid synthesis and high levels of 
citrate are known to inhibit glycolysis 244. Similarly, FAMIN deficiency was shown to 
increase intracellular levels of citrate and reduce rates of glycolysis in macrophages (paper 
II). Hence, this provides additional evidence that macrophage immune function is heavily 
dependent upon metabolic pathways. 
We also show that the metabolic mechanisms of FAMIN were affected by genetic variation 
in LACC1. The studied LACC1 coding variants lead to reduced or loss-of-function functional 
properties of FAMIN. Homozygosity of the substitution of cysteine for arginine at position 
284 (Cys284Arg), which is known to cause EOCD and sJIA 37,206, resulted in a loss of 
FAMIN function and limited the tolerance to endotoxin, while the substitution of isoleucine 
for valine at position 254 (Ile254Val), associated with risk for CD and leprosy 54,188, was 
hypomorphic. In conclusion, in paper II we uncovered a metabolic pathway that controls 
macrophage immune function and can play a role in predisposition for inflammatory and 
infectious disease.  
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3.3 PAPER III: FAMIN IS A PPAR REGULATED PEROXISOME-ASSOCIATED 
PROTEIN 
In paper III, we wanted to further characterize the expression, subcellular localization and 
regulation of LACC1 in human primary cells, cell lines and tissues.  
LACC1 expression in immune-related tissues and cells 
In order to study the endogenous expression of LACC1 and the LACC1-encoded protein 
FAMIN in THP-1 cells, quantitative real-time PCR (qRT-PCR) and WB analyses were 
applied. The LACC1-negative HeLa cell line was transfected with different LACC1 
expressing plasmids in order to characterize FAMIN antibodies to use for further 
experiments. Although all antibodies tested showed specific detection of FAMIN, the 
strongest signal-to-noise ratio was obtained from the E-12 FAMIN antibody and therefore it 
was chosen for the following experiments.  
We then tested LACC1 mRNA expression under PMA differentiation of THP-1 cells. A 50-
fold upregulation of LACC1 mRNA expression was observed in response to PMA 
differentiation in THP-1 cells compared to undifferentiated cells. An additional 2-fold 
upregulation of LACC1 mRNA expression was seen with LPS stimulation. To investigate 
LACC1 gene expression in human tissues, qRT-PCR analyses were performed on human 
tissue cDNA panels from the digestive and immune systems. The analyses showed relatively 
equal expression of LACC1 in all tissues, but with somewhat higher expression detected in 
the immune-related tissues, lymph nodes and spleen. A more extensive characterization of 
FAMIN expression in human white blood cells, by flow cytometry analysis, showed high 
expression in monocytes, neutrophils and DCs (myeloid and plasmacytoid). In contrast, B- 
and T-cells did not show any detectable FAMIN expression. 
Detailed analysis of FAMIN subcellular localization 
THP-1 derived macrophages were used to perform a thorough characterization of FAMIN 
subcellular co-localization, using a panel of antibodies directed towards different organelle 
markers. Results obtained confirmed our previous finding (paper II) of co-localization of 
FAMIN with peroxisome markers PMP70 and catalase. Thus, FAMIN appears to be confined 
to the peroxisomes. In addition, some punctuate co-localization with endomembrane 
structures (endoplasmic reticulum (ER), early endosomes, lysosomes, trans-Golgi and 
mitochondria) was detected. No co-localization could be observed with the structural 
components (fibrillarin, β-tubulin, NUP98, CENP-A and histone H3) of the cell. 
In vitro analysis of FAMIN laccase activity  
We established an assay to measure FAMIN laccase activity based on a standard 
spectrophotometric methodology, where laccase activity was determined by time-series 
measurements of absorbance changes. For this purpose, we used a recombinant human 
FAMIN protein (C-terminal MYC/DDK-tagged) and analyzed its activity using four different 
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phenolic substrates. None of the substrates were oxidized with the recombinant human 
FAMIN, while the fungal laccase from Trametes vesicolor oxidized all substrates.  
Peroxisome proliferator-activated receptor (PPAR) ligands downregulate FAMIN expression 
In order to find potential LACC1 regulatory pathways, we screened 35.000 gene expression 
microarray data and identified 33 genes co-expressed with LACC1 under a number of 
perturbations. These 33 genes were then used to run a gene-set enrichment analysis (GSEA) 
to highlight eventual LACC1-relevant biological pathways using the Kyoto Encyclopedia of 
Genes and Genomes (KEGG 2015) reference knowledgebase. The GSEA identified the 
HSA03320 PPAR signaling pathway as the one most enriched for LACC1 co-expressed 
genes. This prompted us to further explore this finding at the experimental level, by testing 
the effect of PPAR ligands on FAMIN protein expression. We observed that 24hrs treatment 
with PPARα (WY14643) and PPARγ (rosiglitazone) ligands downregulated FAMIN 
expression in PMA-differentiated THP-1 cells (Figure 12). 
 
 
 
Figure 12. Western blot showing PPAR-ligand downregulation of FAMIN expression. PMA-differentiated 
THP-1 cells were treated with PPAR ligands WY14643 or rosiglitazone (ROSI). A clear downregulation of 
FAMIN (48kDa) could be detected after 24hrs with both treatments. β-actin (42kDa) was used as control.  
PPARα ligand treatment has no effect on peroxisome protein expressions 
Because of its localization to peroxisomes, we explored whether depletion of FAMIN 
expression leads to defects in these organelles. We set up an in vitro model system using 
siRNA-mediated downregulation of FAMIN expression in THP-1 cells, which resulted in a 
complete knockdown. However, FAMIN depletion did not have any detectable effect on the 
expression of peroxisome markers PMP70 and catalase, neither did it affect the number or 
size of peroxisomes. This was reproduced (no difference between FAMIN+ and FAMIN- 
cells) when cells were stimulated with the PPARα ligand WY14643, which interestingly 
induced a slight increase in peroxisome number (independent of FAMIN expression). 
To summarize paper III, we provide confirmatory and novel results that contribute to the 
understanding of LACC1 function and involvement in the pathogenesis of immune-mediated 
diseases. Interestingly, the high LACC1 expression pattern detected in spleen, lymph nodes, 
monocytes, DCs and neutrophils resembles the expression pattern of protein tyrosine 
phosphatase non-receptor type 22 (PTPN22) 231, a protein shown to be involved in 
susceptibility to immune-mediated diseases including JIA 245. A SNP-SNP interaction for 
PTPN22 (rs2476601) and LACC1 (rs3764147) has been shown to confer increased risk of 
UC in IBD patients 246, indicating that these two genes may have overlapping mechanisms of 
disease predisposition, through neutrophils or macrophage-specific functions.  
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Very little was known earlier on the expression patterns and the biological function of 
FAMIN. In the first study on FAMIN function, we presented data showing that FAMIN, 
located at the peroxisomes, controls macrophage bioenergetic capacity by promoting DNL 
and FAO (paper II). The peroxisome aspect was also highlighted in the present study 
through an extensive fluorescence microscopy analysis of FAMIN co-localization (paper 
III). We showed that FAMIN appears to be confined to peroxisomes and, to a lower extent, 
endomembrane structures like those found at the level of the ER. The punctuate localization 
of FAMIN to the ER may correspond to nascent FAMIN detected before transport to the 
peroxisomes which would then be consistent with the previous finding of unfolded FAMIN 
(LACC1) mutant (Cys284Arg) retained in the ER (paper II). Peroxisomes have a key role in 
cell lipid metabolism 247 and FAMIN-dependent FAO triggers inflammasome activation and 
ROS production (paper II). Also some of the defense potential of macrophages and 
neutrophils is exerted through the peroxisome content (antimicrobial peptides, peptidases and 
hydrolases) 248. Therefore, maintaining peroxisome homeostasis would be essential for the 
host defense, something that is implied from the observation of decreased peroxisome 
numbers in intestinal epithelial cells from CD patients, showing negative effects on FAO 249.  
The siRNA-mediated knockdown of FAMIN expression did not reveal any direct effect on 
peroxisome numbers. However, GSEA analysis of LACC1 co-expressed genes highlighted 
the PPAR signaling pathway as the top enriched KEGG process. PPARs are transcription 
factors involved in the control of carbohydrate and lipid metabolism, but have also been 
shown to play important anti-inflammatory roles 250. Impaired expression of PPARγ has been 
detected in both UC and CD 251,252. In a mouse model of IBD, animals deficient in 
macrophage-specific PPARγ expression fail to recover after treatment with the PPARγ 
agonist pioglitazone 253. The synthetic PPARα ligand WY14643 and the PPARγ ligand 
rosiglitazone induced FAMIN downregulation in THP-1 macrophages (paper III), 
suggesting the involvement of PPAR pathways in the modulation of LACC1 expression. One 
may speculate that the observed PPAR-driven downregulation of LACC1 expression reflects 
a potential feedback-loop mechanism to control (FAMIN-dependent) FAO rate. At the same 
time, this may represent one genuine mechanism through which PPARs are able to modulate 
inflammation, since downregulation of LACC1 may also result in reduced NLRP3 
inflammasome activation and pro-inflammatory production of ROS. Of interest, it has been 
shown that M1 macrophages can be shifted to M2 phenotype by activation of the PPAR 
pathways 254. Given that LACC1 expression has been detected at higher levels in murine bone 
marrow-derived M1 compared to other macrophage subtypes (paper II), it may be so that 
subtype switches involve PPAR-driven changes in LACC1 expression. However, the 
regulation of FAMIN expression by PPARs needs a more thorough investigation. While the 
precise molecular mechanisms through which LACC1 exerts its biological effects remain to 
be elucidated, these data expand the current knowledge by providing a resource of 
experimental conditions and investigative tools that may be exploited in future LACC1 
functional studies.  
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3.4 PAPER IV: LACC1 LEVELS IN SERA ARE CORRELATED TO DISEASE 
In paper IV, we set up a proteomic high-throughput approach to screen for potential 
candidate biomarkers of diagnostic and/or prognostic value in IBD. Genetic risk effects often 
appear to be mediated by allelic differences (risk vs. non-risk variants) in the modulation of 
mRNA expression (expression quantitative trait loci; eQTLs), something that may be 
reflected in serum protein profiles of patients compared to controls. The protein targets that 
were screened corresponded to genes mapping within the known 163 IBD risk loci, in 
addition to neutrophil-associated and inflammatory proteins. In this paper, we took advantage 
of the Human Protein Atlas (HPA) large repository of antibodies to identify proteins that 
might be of future use for clinical diagnosis and prognostic value. We focused on i) proteins 
that would enable the distinction between IBD patients and healthy individuals; and ii) 
markers that may be useful to differentiate between UC and CD.  
IBD risk proteome screening 
In total 365 antibodies directed against 218 unique target proteins were used for the analysis, 
where sera from 100 IBD patients (CD N = 49 and UC N = 51) were compared with sera 
from 50 healthy controls. When comparing the IBD patients with the controls, we observed 
that antibodies directed against S100 calcium-binding protein A9 (S100A9) and serum 
amyloid proteins A1-A2 (SAA1 and SAA2) were among the top hits in the analyses. Also 
among the top 15 candidate proteins, we found a number of T-cell regulatory proteins 
(CARD11 and BTNL2) 255,256. A few of the proteins in the top 15 have been shown 
previously to be present in sera (CNTF, IL2RA, LNPEP, SAA and S100A9) 257–
261. Interestingly, the protein with the highest significant difference between patients and 
controls was LACC1 (also known as FAMIN), when detected with HPA040150 antibody.  
LACC1 levels are lower in CD and UC patients compared to controls 
The detected sera levels of LACC1 protein were higher in healthy controls compared to CD 
and UC patients. When comparing CD with UC, lower levels of LACC1 protein were 
observed in sera from patients with CD. The results were similar for the two anti-LACC1 
antibodies (HPA040150 and HPA061537), however the anti-LACC1 HPA040150 antibody 
showed generally reduced and more homogeneous results. In order to better characterize this 
antibody, we applied WB analysis of LACC1-transfected cell extracts and confirmed its 
specificity, making it suitable for use in future development of validation tools such as 
sandwich assay and immune-capture mass-spectrometry (IC-MS). Of particular interest, the 
observed LACC1 downregulation in IBD patients compared to healthy controls, with lowest 
expression observed in CD patients, is in concordance with the results obtained for the coding 
variants (Ile254Val and Cys284Arg) in paper II, in that reduced or impaired LACC1 
(FAMIN) expression correlates with disease.  
Other proteins, such as gluthatione peroxidase 4 (GPX4), ubiquillin 4 (UBQLN4) and NOD2, 
showed similar trends as LACC1, when comparing CD with UC. These proteins are involved 
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in protection from oxidative stress, regulation of protein degradation through autophagy and 
intracellular bacterial recognition, respectively 54.  
To summarize paper IV, we found serum levels of the LACC1 protein product to differ 
between IBD patients and healthy controls and to a lower extent also between CD and UC 
patients. This warrants further analyses of LACC1 expression in independent cases and 
controls for eventual consideration of this target as a candidate biomarker to combine with 
other biological predictors.  In this context, and in the light of our recent results on LACC1 
(FAMIN) and fat metabolism (paper II), it is interesting to note that a recent study reported 
the potential use of plasma ether lipid levels to differentiate CD from UC 262. This implies 
that fat metabolism may have a role in IBD, and that in the future a related blood test may be 
developed to distinguish between CD and UC. The identification of specific disease 
biomarker panels for IBD is indeed an intense area of investigation, and other protein targets 
have also been recently highlighted 263.  
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4 CONCLUDING REMARKS 
The work presented in this thesis mainly relates to the characterization of a novel IBD risk 
gene, LACC1, and explores its biology and functional role(s) in IBD. This section further 
discusses the significance of the present findings and possible future directions.  
IBD is known to be a disease of the Western part of the world, however the incidence and 
prevalence is now increasing worldwide 6. Over the past 10 years, which encompass the 
GWAS era, enormous progress has been made in IBD genetics, highlighting pathways and 
plausible pathogenetic mechanisms of disease. However, despite this surge of knowledge, the 
precise etiology of IBD is still mostly unclear.  
This thesis, whose original main aim was the identification and functional characterization of 
novel gastrointestinal disease genes, contributes with valuable new information to improve 
our understanding of IBD etiology and pathophysiology: from the initial identification of the 
CD gene LACC1 as a genetic risk factor also in UC and nsJIA (paper I), to an in-depth 
functional characterization of its protein product FAMIN (paper II), including its expression 
in different cultured and primary cells and human tissues (paper III), and finally the 
discovery of its differential expression in sera form IBD patients versus controls, which is of 
diagnostic biomarker potential (paper IV). Using these studies as a stepping-stone, we now 
have tools and knowledge to further characterize this important gene.  
In paper I, we identified a number of variants in LACC1 associated with IBD, CD, UC and 
nsJIA. Knowledge about the different variants and the associated phenotype could potentially 
be used to identify individuals at risk for disease. IBD is a complex and heterogeneous 
disease where patients could benefit from tailor-made treatments where identification of 
specific genetic risk profiles could contribute to a personalized medical management, i.e. aid 
in the selection of specific treatments for individual patients 264.  
A major finding in this thesis (paper II and III) is the co-localization of FAMIN with FASN 
at the peroxisomes in macrophages. The complex formed between FAMIN and FASN at the 
peroxisome was shown to influence a number of cellular pathways that are key to 
macrophage metabolism, with LACC1 loss-of-function and/or IBD-risk variants leading to 
defects in i) DNL, ii) FAO, iii) inflammasome activation iv) mitochondrial and NADPH-
oxidase dependent production of ROS and v) bactericidal activity. Thus, paper II provides a 
molecular foundation to explain the observed disease phenotype in IBD patients carrying the 
Ile254Val and Cys284Arg LACC1 variants. Furthermore, it provides novel insight into 
metabolic pathways that may be targeted by future IBD treatments, for example by regulating 
FAMIN expression or inducing FAO.  
Our focus in paper II was mainly on macrophage function, therefore at this point we can 
only speculate about the role of LACC1 in neutrophil function/metabolism. Because of the 
key role of neutrophils in IBD 68,265, it would be of great interest to investigate the bactericidal 
function of these cells in the absence of FAMIN. Therefore, future endeavors could be aimed 
at i) characterizing LACC1 function in neutrophils and other immune cells, preferably from 
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IBD patients carrying risk variants, ii) fine-mapping the LACC1 region in order to identify 
new rare variants, iii) identification of substances that upregulate the expression of FAMIN 
and iv) testing the effect of such substances on macrophage and neutrophil 
metabolism/function to investigate potential novel therapeutics. 
The observation that PPAR ligands affect FAMIN expression (paper III) opens up the 
possibility that PPAR ligands may influence macrophage or neutrophil function through 
modulation of FAMIN expression. PPARs are activated by a number of natural (fatty acids) 
and synthetic ligands, and have a role in regulation of lipid and lipoprotein metabolism, 
glucose and energy homeostasis, thereby influencing many different cellular functions 266. 
Additionally, they modulate immune and inflammatory response in distinctive tissues and 
cells 267,268. There are a number of PPAR agonistic and antagonistic drugs available that could 
be tested for their effect on FAMIN and macrophage metabolism and function, as well as in 
our mouse models (mFamin-/-, mFaminp254Ile, mFaminp254Val and mFaminp284Arg). Ultimately, 
such investigations could lead to novel therapeutic management of IBD.  
In paper IV, we identified differentially expressed serum proteins in IBD versus controls and 
in CD versus UC. The serum proteins identified were mainly associated with neutrophils, 
while coming mostly from known IBD risk loci. These results confirm the importance of 
neutrophil biology in IBD, and represent a list of candidate biomarkers that may be further 
investigated and validated in independent case-control cohorts. Proteomic profiles may be 
used as biomarkers, however an “omics” combination of proteome, genotype and 
transcriptome profiling may be best suitable in distinguishing between different diagnoses. 
Recently in IBD, exciting novel data have been reported for microRNA (miRNA) 269,270, 
which show potential to be used as CD versus UC biomarkers 271. miRNA are stable small 
non-coding RNAs that regulate gene expression post-transcriptionally and that can be found 
in most biological fluids 269. In the clinical setting, non-invasive tests are of great value and, 
although in preliminary stages of validation, these recent advances may allow the 
development of novel diagnostic tools. There is little doubt that future integrative approaches, 
where several data layers are combined into unified patients’ profiles, will have a 
considerable impact on the diagnosis and treatment of IBD, implementing “precision 
medicine” approaches to patients management.  
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